Obstructive hypertrophic cardiomyopathy (HCM) is a disease state that has experienced a boom in progress during recent years. Chief among these advances, in terms of improving patient outcomes, has been the cardiac myosin inhibitor class, which recently received endorsement from the American College of Cardiology and American Heart Association in their 2024 update to HCM guidelines.

Although mavacamten holds the title as the first cardiac myosin inhibitor to receive approval for this condition, excitement and anticipation surrounding the potential of aficamten, a next-generation cardiac myosin inhibitor from Cytokinetics, if it were to receive approval from the US Food and Drug Administration. According to the company, a regulatory submission is expected before the close of Q3 2024.

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

https://www.hcplive.com/view/aficamten-in-the-spotlight-at-esc-congress-with-ahmad-masri-md-ms